Ozanezumab

Ozanezumab is a monoclonal antibody designed for the treatment of ALS, also known as Lou Gehrig's disease. It was developed by GlaxoSmithKline, a British multinational pharmaceutical company.

Mechanism of Action[edit | edit source]

Ozanezumab works by targeting a protein called Nogo-A, which is found in high levels in the brain and spinal cord of patients with ALS. Nogo-A is believed to inhibit the growth and repair of nerve cells. By blocking the action of Nogo-A, Ozanezumab may help to slow the progression of ALS.

Clinical Trials[edit | edit source]

Ozanezumab has undergone Phase II clinical trials to evaluate its safety and efficacy in patients with ALS. The results of these trials have been mixed, with some studies showing a slowing of disease progression and others showing no significant effect.

Potential Side Effects[edit | edit source]

As with all medications, Ozanezumab has the potential to cause side effects. These may include allergic reactions, infections, and changes in liver function. Patients should be closely monitored while receiving this medication.

Future Research[edit | edit source]

While the results of clinical trials have been mixed, further research is needed to fully understand the potential benefits and risks of Ozanezumab. This includes ongoing studies to determine the optimal dosage and treatment schedule, as well as studies to explore its potential use in other neurological disorders.